ever it is noteworthy that the restenosis occurred at the ostium of a side branch that was not covered with SES. The clinical outcomes and follow-up QCA results will be available at the time of presentation.Conclusions
In this study, the impact of sirolimus-eluting stents on the outcome of patients with bifurcation lesions in the "real world" experience will be reported. comes. The marked anti-proliferative effects of sirolimus-eluting sterns (SES) raise concerns regarding potential vessel wall thinning and an increase in aneurysm formation.
Methods:
In the randomized double-blind SIRIUS trial (1058 pts), 8-month angiographic follow-up (FU) was obtained in 66% (702 pts). Angiographic aneurysms were defined as treatment site vessel diameter 2 1.5X the normal reference diameter (either at baseline or at FU) and all patients were assessed for clinical events (up to 9 months).
Results:
Aneurysms were found at FU in 6 pts (0.9%); 4 pts with CS (1.1%) and 2 pts with SES (0.6%). In the 4 CS aneurysms 0 FU, 2 were present at baseline and morhphology was fusiform ectasia in 2 (both multiple stents), and eccentric focal (<IO mm length) outpouching in 2 (1 proximal to RCA stent). In the 2 SES aneurysms @ FU, none were present at baseline and morphology was fusiform ectasia in 1 (3 SES after long RCA dissection) and eccentric focal outpouching in 1 (within RCA SES We reporl our experience with the use of the Cypher stent in everyday clinical practice.
Methods:
We included all lesions treated with the Cypher stent in Milan between 15 of April and 30 of August 2002. Major adverse cardiac events (MACE) were defined as death, Q-wave myocardial infarction or target lesion revascularizatron.
Results: Cypher stents were implanted in 217 patients (71% consecutive) to treat 418 lesions. Three hundred fifty-three (84.5%) lesions were complex (ACClAHA classification 82 or higher); 85 (20.3%) were in-stent restenosis and 42 (10.0%) chronic total occlusions. We utilized 2.2t1.6 Cypher stents per procedure (1.2~0.5 per lesion). Intravascular ultrasound guidance was used in 67 (16.0%) lesions. The reference vessel size was 2.8*0.5mm, the minimal lumen diameter (MLD) 0.79*0.48mm and the mean lesion length 18.5+13.8mm.
The total length of Cypherstents used per lesion was 28.0+16.2mm. The maximum inflation pressure used was 15.7+3.4 atm and the balloon to artery ratio 1.1*0.3. The postprocedure MLD was 2.81*0.47mm, resulting in acute gain of 2.0*0.6mm.
The clinical success rate was 99%. One patient required urgent coronary artery bypass surgery and died the next day and one had a Q-wave myocardial infarction during the procedure.
Clinical follow-up at 1.720.5 months has been completed in 176 patients (97.8%) without detection of any other MACE. Six-month clinical follow-up will be available at the time of presentabon. Follow-up coronary angiography is planned for all patients nine months post-procedure and it is estimated to be accomplished in about 250 lesions at the time of presentation. Conclusions:
The implantation of Cypher stents in "real world lesions", aiming to completely cover the diseased segment, results in high stented vessel lengths.
Thirly days complications are low without an increase in thrombosis, despite usage of long and multiple stents. We will see if follow-up results are in accordance with prior findings in less complex lesions.
1030-l 85
Is There Any Arterial Toxic Effect After Overlapping Siroiimus-Eluting Stents? has a toxic effect on the vessel wall.
Objective:
The purpose of this study was to analyse the one-year IVUS findings after 2 overlapping Sirolimus-eluting stems were implanted in patients with native artery ISR lesions.
Methods:
Cf 25 patients in the ISR Sirolimus registry, 8 had a lesion length requiring 2 stents for full lesion coverage. Per protocol, these stents were implanted with a >l mm of overlap. Volumetric intravascular ultrasound (IVUS) was performed immediately and one year after implantation.
